Ge Long Hui·2025-08-20 13:24Core Insights - The company reported a revenue of 382 million RMB in the first half of 2025, representing a year-on-year growth of 26% [1] - The net loss attributable to shareholders was 13.49 million RMB, significantly reduced from a net loss of 225 million RMB in the same period last year [1] - The net cash flow from operating activities was 11.28 million RMB, a substantial improvement from a negative cash flow of 214 million RMB in the previous year [1] Financial Performance - The gross profit margin reached 82.54%, an increase of 12.68 percentage points year-on-year, with a 5.14 percentage point increase when excluding overflow costs from the previous year [1] - The company implemented cost reduction and efficiency improvement measures, resulting in significant savings across multiple expense categories during the reporting period [1] Vaccine Sales and Market Position - The sales revenue from the meningococcal conjugate vaccine was approximately 364 million RMB, reflecting a year-on-year growth of 38.43% [1] - The product, known as Manhaixin®, is the only quadrivalent meningococcal conjugate vaccine in the Chinese market, and its increasing market share contributed to the overall revenue growth of 26% [1]